{"id":"W2793366594","doi":"10.1200/jco.2018.36.6_suppl.276","title":"Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Enzalutamide; Abiraterone acetate; Prostate cancer; Cabazitaxel; Clinical trial; Oncology; Abiraterone; Internal medicine; Cost effectiveness; Cancer; Androgen deprivation therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02740747,0.001003331,0.001416025,0.007284945,0.0004311288,0.003489709,0.001426231,0.0009572725,0.004512062],"category_scores_gemma":[0.09103466,0.0003491477,0.003652504,0.006429546,0.0009134306,0.001675357,0.002308988,0.001767712,0.0004630277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004477002,"about_ca_system_score_gemma":0.004019083,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008178885,"about_ca_topic_score_gemma":0.007426035,"domain_scores_codex":[0.9731429,0.01810814,0.001475464,0.0006996351,0.006003079,0.0005708279],"domain_scores_gemma":[0.9495708,0.03708437,0.006714519,0.001154971,0.004252084,0.001223262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01220234,0.001069101,0.3009953,0.004376685,0.00872828,0.0003485215,0.0006535407,0.1181127,0.001076688,0.05191372,0.05699487,0.4435284],"study_design_scores_gemma":[0.003703415,0.007105326,0.4329509,0.005045079,0.003866995,0.001229488,0.001026265,0.3343427,0.002294259,0.1151296,0.0927657,0.0005403239],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5863318,0.04932478,0.1576554,0.01370107,0.000660623,0.01422477,0.06376739,0.000747419,0.1135868],"genre_scores_gemma":[0.9292027,0.001515329,0.0546894,0.0009608501,0.0001338198,0.003393824,0.008893927,0.0000806082,0.001129496],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02740747,"threshold_uncertainty_score":0.1449463,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1308920635682776,"score_gpt":0.526600887928451,"score_spread":0.3957088243601733,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}